Protalix BioTherapeutics
PLX
PLX
28 hedge funds and large institutions have $11.5M invested in Protalix BioTherapeutics in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less call options, than puts
Call options by funds: $261K | Put options by funds: $348K
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Holders
28
Holding in Top 10
–
Calls
$261K
Puts
$348K
Top Buyers
| 1 | +$1.97M | |
| 2 | +$291K | |
| 3 | +$174K | |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$142K |
| 5 |
BlackRock
New York
|
+$139K |
Top Sellers
| 1 | -$3.35M | |
| 2 | -$2.13M | |
| 3 | -$1.78M | |
| 4 |
AGC
Angelo Gordon & Co
New York
|
-$470K |
| 5 |
Jane Street
New York
|
-$273K |